

**ORSERDU
(elacestrant)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older
Female patients **MUST** be postmenopausal

Diagnosis

Patient must have the following:

1. Advanced or metastatic breast cancer
 - a. ER-positive, HER2-negative
 - b. Presence of ESR1 mutation in plasma specimen using an FDA-approved test
 - c. Patient has had disease progression following at least one line of endocrine therapy

AND ALL of the following:

- a. Prescriber agrees to monitor the patient's lipids
- b. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Orserdu and for 1 week after the last dose

Prior - Approval Limits

Quantity

Strength	Daily Dosing Limits
86 mg	345 mg per day
345 mg	

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older
Female patients **MUST** be postmenopausal

**ORSERDU
(elacestrant)**

Diagnosis

Patient must have the following:

1. Advanced or metastatic breast cancer
 - a. ER-positive, HER2-negative
 - b. Presence of ESR1 mutation in plasma specimen using an FDA-approved test

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor the patient's lipids
- c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Orserdu and for 1 week after the last dose

Prior - Approval *Renewal* Limits

Same as above